Breaking News Instant updates and real-time market news.

DD

Changed to DWDP

$69.65

0.15 (0.22%)

, SQ

Square

$11.25

-0.09 (-0.79%)

10:33
10/19/16
10/19
10:33
10/19/16
10:33

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DuPont (DD) initiated with a Buy at Nomura. 2. Square (SQ) initiated with a Neutral at Credit Suisse. 3. GoDaddy (GDDY) initiated with a Buy at Cantor. 4. Wix.com (WIX) was initiated with a Buy at Cantor while the firm initiated Web.com (WEB) initiated with a Hold. 5. Amarin (AMRN) initiated with a Buy at Citi. The firm has a $5 price target on the stock. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

DD

Changed to DWDP

$69.65

0.15 (0.22%)

SQ

Square

$11.25

-0.09 (-0.79%)

GDDY

GoDaddy

$35.97

0.455 (1.28%)

WIX

Wix.com

$44.20

0.3 (0.68%)

WEB

Web.com

AMRN

Amarin

$3.00

0.01 (0.33%)

  • 23

    Oct

  • 01

    Nov

  • 02

    Nov

  • 03

    Nov

  • 10

    Nov

  • 10

    Nov

DD Changed to DWDP
$69.65

0.15 (0.22%)

10/18/16
NOMU
10/18/16
INITIATION
Target $78
NOMU
Buy
DuPont initiated with a Buy at Nomura
Nomura analyst Aleksey Yefremov initiated DuPont (DD) with a Buy and a $78 price target saying the the Dow (DOW) merger will generate above-trend growth in earnings and FCF for the next three years and for the valuation discount to improve.
10/10/16
UBSW
10/10/16
UPGRADE
Target $62
UBSW
Buy
Dow Chemical upgraded to Buy from Neutral at UBS
UBS analyst John Roberts upgraded Dow Chemical (DOW) to Buy saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." The analyst sees $3B in potential cost savings and expects improving cash flow. Roberts raised his price target for the shares to $62 from $53.
10/03/16
10/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) and DuPont (DD) were upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing he opportunity presented by the proposed merger. 2. Freeport McMoRan (FCX), Barrick Gold (ABX), and Pan American Silver (PAAS) were upgraded to Buy from Hold at Deutsche Bank. 3. LogMeln (LOGM) upgraded to Overweight from Equal Weight at Barclays with analyst Raimo Lenschow saying the pending merger with Citrix's (CTXS) divested GoTo assets creates a "great new opportunity." 4. Halliburton (HAL) upgraded to Buy from Hold at Societe General. 5. Coty (COTY) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying she believes Coty is at the beginning of a potential transformation with the pending closure of the P&G Beauty deal this week that could bring increased scale as well as a more targeted operational structure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Citi upgrades Dow and DuPont, says DowDuPont could be 'stock to own' in 2017
As previously reported, Citi analyst P.J. Juvekar upgraded shares of both Dow Chemical (DOW) and DuPont (DD), each to Buy from Hold, citing their "massive" cost-cutting opportunity after their proposed merger goes through as well as the potential for upside to the companies' stated $3B synergy target. If their deal gets completed, the combined Dow-DuPont would "be the stock to own in 2017," said Juvekar, who raised the firm's price target on DuPont shares to $76 from $72 and increased the target for Dow shares to $59 from $55.
SQ Square
$11.25

-0.09 (-0.79%)

08/29/16
STFL
08/29/16
NO CHANGE
STFL
Square lending program has limited risk, says Stifel
Stifel analyst Scott Devitt believes that the risk facing Square's lending program, Square Capital, is limited. He notes that Square sells loans to investors and keeps less than 10% of the outstanding loans on its balance sheet. Devitt keeps a $15 price target and Buy rating on the shares.
10/19/16
FBCO
10/19/16
INITIATION
Target $12
FBCO
Neutral
Square initiated with a Neutral at Credit Suisse
Credit Suisse analyst Paul Condra initiated Square with a Neutral and $12 price target citing full valuation.
09/02/16
RBCM
09/02/16
NO CHANGE
RBCM
Square believes EBITDA can continue to rise, says RBC Capital
RBC Capital says Square's CFO believes that its significant EBITDA increase in Q2 was "not an isolated event." The CFO says that the company's profits over the longer term will be boosted by increases in the number of large merchants using the service, by the reacceleration of Square Capital, and by additional ancillary services, RBC Capital reported.
08/29/16
08/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Harley-Davidson (HOG) downgraded to Underperform from Neutral at Longbow, with analyst David MacGregor telling investors that his dealer checks indicate wholesale shipments at the low end of the guidance range. MacGregor expects an increasingly competitive market environment and does not see a positive catalyst for shares over the next 18 months. 2. Autodesk (ADSK) downgraded to Underweight from Neutral at MUFG, as analyst Stephen Bersey said he has "far-less conviction" in his estimates given his and management's limited visibility about the current and future business trends. The analyst keeps a $50 rice target for the shares following the company's Q2 results. 3. Square (SQ) downgraded to Neutral from Buy at BTIG by analyst Mark Palmer, who views the stock as fairly valued following the recent rally. 4. Signet Jewelers (SIG) downgraded to Accumulate from Buy at Johnson Rice, with analyst David Mann citing comps declines at all three its U.S. divisions, which he expects to continue in the second half. The slower comps at Zales are particularly disconcerting, Mann tells investors. 5. Fiesta Restaurant (FRGI) downgraded to Neutral from Overweight at Piper Jaffray, with analyst Nicole Miller Regan citing uncertainty following the unexpected retirement of the company's' long-standing CEO and the board's decision to reevaluate strategic plans. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
GDDY GoDaddy
$35.97

0.455 (1.28%)

10/18/16
CANT
10/18/16
INITIATION
Target $42
CANT
Buy
GoDaddy initiated with a Buy at Cantor
Cantor initiated GoDaddy with a Buy and a $42 price target.
10/03/16
SMTR
10/03/16
INITIATION
Target $41
SMTR
Buy
GoDaddy initiated with a Buy at Summit Redstone
Summit Redstone analyst Jonathan Kees initiated GoDaddy with a Buy and a $41 price target.
10/03/16
10/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. 3D Systems (DDD) coverage transferred with a Market Perform at FBR Capital. 2. Carnival (CCL) initiated with a Buy at HSBC. 3. GoDaddy (GDDY) initiated with a Buy at Summit Redstone. 4. Versum Materials (VSM) initiated with a Buy at Seaport Global. 5. ExOne (XONE) coverage transferred with an Outperform at FBR Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/16
OPCO
09/26/16
NO CHANGE
OPCO
Outperform
Oppenheimer 'increasingly confident' on GoDaddy long-term strategy
Oppenheimer analyst Jason Helfstein is "increasingly confident" of GoDaddy's long-term strategy and value creation after meeting with the company's management. The analyst expects annual average revenue per customer, or ARPU, to be the main driver of top-line growth, driven by attachment opportunities and product expansions. Helfstein believes the shares appear attractive given the focus on free cash flow generation and under-leveraged capital structure. He reiterates an Outperform rating on the shares.
WIX Wix.com
$44.20

0.3 (0.68%)

09/21/16
JPMS
09/21/16
DOWNGRADE
Target $50
JPMS
Neutral
Wix.com downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Sterling Auty downgraded Wix.com to Neutral citing valuation with the stock up 100% year-to-date. The analyst raised his price target for the shares to $50 from $46 but does not see enough upside to justify an Overweight rating.
10/18/16
CANT
10/18/16
INITIATION
Target $52
CANT
Buy
Wix.com initiated with a Buy at Cantor
Cantor initiated Wix.com with a Buy and a $52 price target.
09/23/16
RBCM
09/23/16
DOWNGRADE
RBCM
Sector Perform
Wix.com downgraded on valuation at RBC Capital
As noted earlier, RBC Capital downgraded Wix.com to Sector Perform from Outperform. Analyst Mark Mahaney downgraded the stock based on valuation. Target $45.
09/22/16
RBCM
09/22/16
DOWNGRADE
RBCM
Sector Perform
Wix.com downgraded to Sector Perform from Outperform at RBC Capital
WEB Web.com

02/24/16
PIPR
02/24/16
NO CHANGE
Target $31
PIPR
Overweight
Web.com shares should move closer to fair value, says Piper Jaffray
Piper Jaffray analyst Gene Munster says Yodle's ability to help Web.com return to growth will "assist in re-rating shares closer to fair value." The analyst expects estimates for Web.com to move higher after the Yodle acquisition closes in March. He views the stock as one of the most favorable risk/rewards in his coverage universe. Munster has an Overweight rating on the name with a $31 price target.
10/18/16
CANT
10/18/16
INITIATION
Target $20
CANT
Hold
Web.com initiated with a Hold at Cantor
Cantor initiated Web.com with a Hold and a $20 price target.
05/09/16
ROTH
05/09/16
NO CHANGE
Target $28
ROTH
Buy
Web.com strategy to set pace for growth acceleration, says Roth Capital
Roth Capital analyst Jeff Martin expects Web.com's efforts to transform the business via the Yodle acquisition to result in multi-year revenue growth acceleration, starting in 2017. The analyst believes that the benefit of the transition to faster-growth and higher value-added services in emerging market opportunities depends on the ability to allocate resources and improve retention of legacy offerings, which the company "does well." Martin notes Web.com's Q1 results were "healthy" and reiterates a Buy rating and $28 price target on the shares.
06/24/16
PIPR
06/24/16
NO CHANGE
Target $31
PIPR
Overweight
Web.com should be bought on weakness, says Piper Jaffray
Piper Jaffray analyst Gene Munster recommends buying Web.com's shares on this morning's pullback, following the U.K. vote to leave the EU. The analyst believes the company has only a "very small" revenue exposure to Europe and expects its U.S. business to see no impact from the "Brexit" vote. As Yodle is integrated and lapped, Web.com will return to an organic top-line growth rate in the mid-single digits, Munster tells investors in a research note. He reiterates an Overweight rating and $31 price target on the shares. In morning trading, Web.com's stock has dropped almost 4% to $17.31 per share.
AMRN Amarin
$3.00

0.01 (0.33%)

10/04/16
CANT
10/04/16
INITIATION
Target $6
CANT
Buy
Amarin initiated with a Buy at Cantor
Cantor initiated Amarin with a Buy and a $6 price target.
05/12/16
05/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amarin (AMRN) assumed with a Buy at Jefferies by analyst Hugo Ong, who said off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit. 2. Theravance Biopharma (TBPH) initiated with an Outperform at Leerink with analyst Paul Matteis saying he sees a favorable risk/reward ahead of a string of clinical/commercial catalysts over the next year. 3. Graphic Packaging (GPK) initiated with a Conviction Buy at Goldman. 4. Owens-Illinois (OI) initiated with a Sell at Goldman. 5. Sonoco Products (SON) initiated with a Neutral at Goldman. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/12/16
JEFF
05/12/16
INITIATION
Target $3.5
JEFF
Buy
Amarin assumed with a Buy at Jefferies
Jefferies analyst Hugo Ong assumed coverage of Amarin with a Buy rating and $3.50 price target. Ooff-label Vascepa promotion in mixed dyslipidemia may be "beginning to bear fruit," Ong tells investors in a research note.
10/19/16
SBSH
10/19/16
INITIATION
Target $5
SBSH
Buy
Citi starts Amarin with Buy rating, $5 price target
Citi analyst Joel Beatty initiated Amarin with a Buy rating and $5 price target. The biopharmaceutical company closed yesterday up 1c to $3.00. If the ongoing REDUCE-IT outcomes trial for the company's sole drug Vascepa is positive in late 2017 or early 2018, the label will be expanded to treat adults with triglycerides greater than or equal to 150, which is almost a 20 times larger market than the drug's current indication, Beatty tells investors in a research note. The analyst estimates the stock would trade up to $16 per share on news of a positive trial. In this scenario, he models Vascepa sales peaking at $2.6B in 2024.

TODAY'S FREE FLY STORIES

ESRX

Express Scripts

$61.00

-1.01 (-1.63%)

14:25
09/20/17
09/20
14:25
09/20/17
14:25
Options
Express Scripts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 25

    Oct

14:25
09/20/17
09/20
14:25
09/20/17
14:25
General news
FX Action: The dollar rose, then fell, then rose again »

FX Action: The dollar…

14:25
09/20/17
09/20
14:25
09/20/17
14:25
Conference/Events
Federal Reserve Chairperson Yellen holds a press conference »

Following a quarterly…

CVS

CVS Health

$81.68

-1.42 (-1.71%)

, WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

14:20
09/20/17
09/20
14:20
09/20/17
14:20
Hot Stocks
Pharmacies drop after Leerink says Amazon talking to PBMs »

After speaking with…

CVS

CVS Health

$81.68

-1.42 (-1.71%)

WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

ESRX

Express Scripts

$61.00

-1.01 (-1.63%)

ABC

AmerisourceBergen

$78.74

-0.54 (-0.68%)

CAH

Cardinal Health

$66.44

0.179 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 17

    Oct

  • 22

    Oct

  • 25

    Oct

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

14:20
09/20/17
09/20
14:20
09/20/17
14:20
Recommendations
Alnylam analyst commentary  »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

14:20
09/20/17
09/20
14:20
09/20/17
14:20
General news
Treasury Action: yields knee-jerked higher »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

14:17
09/20/17
09/20
14:17
09/20/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/20/17
09/20
14:16
09/20/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKS

Skyworks

$107.93

0.44 (0.41%)

14:15
09/20/17
09/20
14:15
09/20/17
14:15
Options
Skyworks put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

14:15
09/20/17
09/20
14:15
09/20/17
14:15
General news
FOMC announced balance sheet runoff in October and left rates unchanged »

FOMC announced balance…

14:15
09/20/17
09/20
14:15
09/20/17
14:15
General news
Breaking General news story  »

Fed Chair Press…

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

, SPX

S&P 500

14:13
09/20/17
09/20
14:13
09/20/17
14:13
Technical Analysis
Technical View: S&P 500 slips below the pivot low »

The S&P 500 (SPX) is…

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZRX

PhaseRx

$0.78

0.055 (7.64%)

14:11
09/20/17
09/20
14:11
09/20/17
14:11
Hot Stocks
PhaseRx confirms receipt of FDA orphan drug designation for PRX-ASL »

PhaseRx announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$49.34

0.24 (0.49%)

14:10
09/20/17
09/20
14:10
09/20/17
14:10
Hot Stocks
Sanofi reports 'potential breakthrough' in preclinical work on HIV antibodies »

Researchers working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SPX

S&P 500

14:06
09/20/17
09/20
14:06
09/20/17
14:06
General news
Fed details plans to being reducing balance sheet »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$14.06

0.29 (2.11%)

14:05
09/20/17
09/20
14:05
09/20/17
14:05
Options
Valeant call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

, SPX

S&P 500

14:04
09/20/17
09/20
14:04
09/20/17
14:04
General news
Federal Reserve maintains median projection for year-end funds rate at 1.4% »

The Fed's "dot…

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:02
09/20/17
09/20
14:02
09/20/17
14:02
General news
Fed says economic activity rising moderately this year »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$68.25

-0.24 (-0.35%)

, SYMC

Symantec

$34.16

0.39 (1.15%)

14:02
09/20/17
09/20
14:02
09/20/17
14:02
Periodicals
Breaking Periodicals news story on Splunk, Symantec »

Symantec 'play'…

SPLK

Splunk

$68.25

-0.24 (-0.35%)

SYMC

Symantec

$34.16

0.39 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SPX

S&P 500

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
Fed plans to initiate balance sheet normalization in October »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
FOMC Meeting Announcement Federal Funds Rate data reported »

FOMC Meeting Announcement…

14:00
09/20/17
09/20
14:00
09/20/17
14:00
General news
Breaking General news story  »

Federal Reserve leaves…

RNVA

Rennova Health

$0.22

-0.0021 (-0.93%)

13:55
09/20/17
09/20
13:55
09/20/17
13:55
Conference/Events
Rennova Health to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MLCO

Melco Resorts & Entertainment

$23.78

0.77 (3.35%)

13:50
09/20/17
09/20
13:50
09/20/17
13:50
Options
Bullish option play opened in Melco Resorts as shares tick to 52-week highs »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

, UNH

UnitedHealth

$195.34

0.69 (0.35%)

13:48
09/20/17
09/20
13:48
09/20/17
13:48
Periodicals
McConnell intends to consider healthcare bill in Senate next week, WSJ says »

A spokesman for Senate…

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

UNH

UnitedHealth

$195.34

0.69 (0.35%)

CNC

Centene

$90.10

0.32 (0.36%)

WCG

WellCare

$166.10

-2.065 (-1.23%)

CI

Cigna

$181.44

-0.07 (-0.04%)

ANTM

Anthem

$181.90

0.46 (0.25%)

HNT

Health Net

HUM

Humana

$238.58

-1.46 (-0.61%)

AET

Aetna

$154.56

-1.48 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.